



AP-1 γ 2 is an adaptor protein 1 variant required for endosome-to-Golgi trafficking of the mannose-6-P receptor (CI-MPR) and ATP7B copper transporter

Received for publication, July 22, 2023, and in revised form, January 18, 2024. Published, Papers in Press, February 1, 2024.

<https://doi.org/10.1016/j.jbc.2024.105700>

Lucas Alves Tavares¹, Roger Luiz Rodrigues¹, Cristina Santos da Costa¹, Jonas Alburquerque Nascimento¹, Julianne Vargas de Carvalho¹, Andreia Nogueira de Carvalho¹, Gonzalo A. Mardones², and Luis L. P. daSilva^{1,*}

From the ¹Center for Virology Research and Department of Cell and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil; ²Escuela de Medicina, Facultad de Medicina y Ciencia, Universidad San Sebastián, Valdivia, Chile

Reviewed by members of the JBC Editorial Board. Edited by Phyllis Hanson

Selective retrograde transport from endosomes back to the trans-Golgi network (TGN) is important for maintaining protein homeostasis, recycling receptors, and returning molecules that were transported to the wrong compartments. Two important transmembrane proteins directed to this pathway are the Cation-Independent Mannose-6-phosphate receptor (CI-MPR) and the ATP7B copper transporter. Among CI-MPR functions is the delivery of acid hydrolases to lysosomes, while ATP7B facilitates the transport of cytosolic copper ions into organelles or the extracellular space. Precise subcellular localization of CI-MPR and ATP7B is essential for the proper functioning of these proteins. This study shows that both CI-MPR and ATP7B interact with a variant of the clathrin adaptor 1 (AP-1) complex that contains a specific isoform of the γ -adaptin subunit called γ 2. Through synchronized anterograde trafficking and cell-surface uptake assays, we demonstrated that AP-1 γ 2 is dispensable for ATP7B and CI-MPR exit from the TGN while being critically required for ATP7B and CI-MPR retrieval from endosomes to the TGN. Moreover, AP-1 γ 2 depletion leads to the retention of endocytosed CI-MPR in endosomes enriched in retromer complex subunits. These data underscore the importance of AP-1 γ 2 as a key component in the sorting and trafficking machinery of CI-MPR and ATP7B, highlighting its essential role in the transport of proteins from endosomes.

The sorting of transmembrane proteins in the late secretory pathway relies on physical interactions between targeting signals in their cytosolic domains and adaptor proteins found in transport vesicle coats. These interactions determine the efficiency and specificity of sorting, influencing transmembrane proteins' localization, processing, and function. Within this context, two types of transmembrane receptors, the Cation-

Dependent Mannose-6-phosphate Receptor (CD-MPR) and the Cation-Independent MPR (CI-MPR), are responsible for delivering soluble lysosomal hydrolases tagged with Mannose-6-phosphate (M6P) residues from the trans-Golgi network (TGN) to early endosomes using clathrin-coated vesicles (CCVs) (1–3). The acidic environment of endosomes facilitates the dissociation of MPRs from their ligands (4–6), and the receptors are recycled back to the TGN for further rounds of transport (7–12).

In addition to sorting hydrolases, CI-MPR can interact with non-M6P-containing ligands, such as insulin-like growth factor II (IGF-II), earning the alternative name of IGF-II receptor. As a result, CI-MPR serves other functions, including cell mobility, growth, and regulation of apoptosis (13–15). Therefore, CI-MPR is thought to follow a more intricate cellular pathway than CD-MPR, being directed from the TGN and endosomes to the plasma membrane, where it is subsequently endocytosed and eventually returned to endosomes and the TGN (7–12).

Similarly, the P-type ATPase copper transporters ATP7A and ATP7B are critical in maintaining cellular copper homeostasis by shuttling between the TGN, endosomes, and the plasma membrane. Copper is an essential micronutrient necessary for the function of oxygen-dependent enzymes; however, an excessive accumulation of Cu⁺ can be toxic. ATP7A is expressed in various tissues, while ATP7B is primarily found in the liver, with lower expression levels in the brain and kidney (16). Under basal conditions, ATP7A and ATP7B are primarily localized in the TGN (17, 18). However, when intracellular copper levels rise, these transporters redistribute from the TGN to peripheral cytoplasmic vesicles and the cell surface, enabling them to efflux excess copper from the cytosol. Following decreased copper levels, ATP7A and ATP7B return to the TGN to maintain homeostasis (19–22).

The intracellular trafficking of MPRs and ATP7A/B involves the clathrin adaptor protein complex 1 (AP-1) (23, 24). AP-1 belongs to a family of five heterotetrameric complexes (25, 26), and is potentially the most versatile AP with the largest number of subunit isoforms reported. These include two γ (1

* For correspondence: Luis L. P. daSilva, lldasilva@fmrp.usp.br.

Present address for Julianne Vargas de Carvalho: Center for Cell-Based Therapy, Hemotherapy Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; Condensed title: CI-MPR and ATP7B retrograde transport requires AP-1 γ 2.

CI-MPR and ATP7B retrograde transport requires AP-1 γ 2

and γ 2), two μ 1 (μ 1A and μ 1B), three σ 1 (σ 1A, σ 1B, and σ 1C), and a single β (β 1) subunit that may form alternative complexes (27). The interaction of AP-1 with the cytosolic tail of transmembrane proteins occurs *via* at least two types of sorting signals (1): the dileucine-based motif ((D/E)xxxL(L/I/M)), which interacts with the hemicomplex composed by γ / σ 1 subunits (28–30); and (2) the tyrosine-based motif (Y_{xx}Ø), which interacts with the μ 1 subunits (31–33).

AP-1 has initially been implicated in the packaging at the TGN of CI-MPR into CCVs destined for early endosomes (34–37). Additionally, AP-1 was reported to mediate the retrograde trafficking of CI-MPR from the early endosomes to the TGN (37–42). Furthermore, the proper retrograde transport of ATP7B from endosomes to the TGN relies on the intact dileucine motif present in the C-terminal tail of ATP7B (22, 43–45), and functional AP-1 (45–47). Notably, AP-1 physically interacts with ATP7B, which is crucial for retrieving ATP7B from endosomes to the TGN (44, 45, 47).

Importantly, these studies on the function of AP-1 in CI-MPR and ATP7B trafficking assessed only the roles of μ 1A or γ 1 subunits but not the γ 2 subunit isoform. Previous studies demonstrated that γ 2 may form an AP-1 complex variant (30, 48), herein termed AP-1 γ 2 (Fig. 1A), but knowledge is limited regarding the cellular roles played by this alternative AP-1 complex. Depletion of γ 2, but not γ 1, impairs the targeting of endocytosed Epidermal Growth Factor (EGF) Receptor-EGF complexes for degradation *via* the multivesicular body pathway (49–51). In addition, γ 2 was shown to be required for HIV-1 Nef-mediated targeting of CD4 and MHC-I for lysosomal degradation (51, 52).

Here, we show that AP-1 γ 2 interacts with CI-MPR and ATP7B, and is required for proper subcellular distribution of these transmembrane proteins. Although AP-1 γ 2 is dispensable for CI-MPR and ATP7B export from the TGN, the depletion of AP-1 γ 2 significantly disrupts the retrograde trafficking of CI-MPR and ATP7B from endosomes to the TGN, leading to an aberrant increase in cell surface localization. Specifically, in cells lacking AP-1 γ 2, an endocytosed CI-MPR-based reporter fails to reach the TGN and accumulates in endosomes enriched in retromer components. This observation leads us to suggest that AP-1 γ 2 is essential for the optimal functioning of retrograde transport carriers formed in early endosomes and destined to the TGN. Taken together, the data underscores the importance of AP-1 γ 2 as a key component in the sorting and trafficking machinery of CI-MPR and ATP7B, highlighting its essential role in the transport of proteins from endosomes.

Results

CI-MPR interacts with AP-1 complex variants containing either γ 1 or γ 2 subunits

The AP-1 γ 1 complex variant has been strongly associated with bidirectional CI-MPR trafficking between the TGN and endosomes (23), but the involvement of the AP-1 γ 2 variant remains at issue. To investigate the interaction of CI-MPR with both AP-1 γ 1 and AP-1 γ 2 variants (Fig. 1A), we first

performed yeast two-hybrid assays using the CI-MPR cytosolic tail (CI-MPR_CT) and the μ subunit of different AP complexes. The cytosolic tail of TGN38 and Lamp2a served as positive controls for μ subunit interactions (53). We found a robust interaction of CI-MPR_CT with the μ 1A subunit of AP-1 and its polarized epithelial cell-specific isoform μ 1B (25). This interaction is disrupted by a Y/A substitution in the CI-MPR_CT tyrosine-based motif (₂₃₅₃YSKV_{2356/2353}ASKV₂₃₅₆) (Fig. 1B). Consistent with previous findings, the μ 1A tyrosine-binding pocket (54) is also essential for CI-MPR_CT binding (Fig. 1C). These data were confirmed by GFP-Trap co-IP assays showing that μ 1A-GFP interacts with endogenous CI-MPR from cell lysates and that this interaction was compromised by mutating the μ 1A tyrosine-binding pocket (Fig. 1D). Importantly, co-IP of endogenous γ 1 and γ 2 subunits indicate that μ 1A-GFP incorporates into either AP-1 γ 1 or AP-1 γ 2 complex variants. As expected, incorporation was not prevented by the tyrosine-binding pocket mutation (Fig. 1D). To further investigate if CI-MPR binds the AP-1 variant containing γ 2, we performed co-IP assays with the endogenous CI-MPR. The results show that both γ 1 and γ 2 precipitate with CI-MPR (Fig. 1E), indicating their ability to form complexes with this receptor.

The γ 2 adaptin is essential for normal CI-MPR intracellular distribution

Given that CI-MPR interacts with AP-1 complexes containing either γ 1 or γ 2, to confirm that μ 1A serves as a shared subunit for both complexes, we investigated the behavior of γ 1 and γ 2-adaptins in HeLa μ 1A CRISPR/Cas9 KO cells (55). Co-immunostaining of γ 1 and γ 2 in HeLa cells shows their partially distinct subcellular distribution (Fig. S1, A and F), confirming our previous observations (51, 52). Notably, the punctate patterns of γ 1 or γ 2 were lost in μ 1A KO cells (Fig. S1B) but were rescued upon expression of either μ 1A(WT)-GFP or tyrosine-binding pocket mutants of μ 1A-GFP (Fig. S1, C–F). Western blot analysis of total cell extracts confirmed that μ 1A depletion causes a strong decrease in the overall levels of γ 1 and γ 2, which are restored by the expression of μ 1A(WT)-GFP (Fig. S1G). Therefore, the stability of both AP-1- γ 1 and AP-1- γ 2 complex variants depends on μ 1A subunit expression, a phenotype previously reported (51, 52). Importantly, these results support that both γ 1 and γ 2-adaptins are components of AP-1 complex variants containing μ 1A.

Since the stability of both γ 1 and γ 2 adaptins is dependent on μ 1A subunit expression, we initially investigated CI-MPR trafficking in the context of γ 1/ γ 2 co-depletion by using μ 1A KO cells. In WT cells, CI-MPR localized mainly at the juxta-nuclear region in close association with the Golgi marker Giantin (Fig. S2A). In μ 1A KO cells, Giantin labeling itself appears slightly more dispersed, a possible consequence of changes in Golgi organization resulting from protein trafficking alterations previously reported for these cells (55). Nevertheless, CI-MPR showed a strongly dispersed pattern and reduced proximity to the Golgi marker (Fig. S2, B and C).




Figure 1. CI-MPR interacts with both AP-1 γ 1 and AP-1 γ 2 complex variants. *A*, schematic representation of the AP-1 complex variants comprising either γ -adaptin isoforms, γ 1 or γ 2, which form complexes termed AP-1 γ 1 and AP-1 γ 2, respectively, together with the other three subunits: β 1, μ 1, and σ 1. *B*, yeast two-hybrid assays of CI-MPR cytosolic tail (CI-MPR_CT) with the medium subunits (μ) of AP-1 to AP-4. Yeast growth in medium without histidine (-HIS) indicates interaction between the proteins tested. *C*, evaluation of CI-MPR interaction with μ 1A containing two individual mutations in its tyrosine-binding pocket. Reduced yeast growth indicates that both μ 1A mutants are defective in the interaction with CI-MPR_CT or TGN38_CT. *D*, GFP-Trap Co-IP assays using lysates of HEK cells expressing GFP, μ 1A(WT)-GFP, μ 1A(W408S)-GFP or μ 1A(D174A)-GFP. CI-MPR co-IP with μ 1A(WT)-GFP at higher levels compared to GFP, μ 1A(W408S)-GFP or μ 1A(D174A)-GFP. Input represents 5% of cell lysates used in the Co-IP assays. *E*, HeLa cell lysates were subjected to immunoprecipitation with anti-CD4 (negative control) or anti-CI-MPR antibodies. The samples were then processed for SDS-PAGE and Western blot for CI-MPR, γ 1, γ 2, and GAPDH. Input represents 1% of the samples.

CI-MPR and ATP7B retrograde transport requires AP-1 γ 2

Altered CI-MPR colocalization with Giantin was restored in μ 1A KO cells expressing μ 1A-GFP WT, but not in cells expressing μ 1A(D174A)-GFP or μ 1A(W408S)-GFP mutants (Fig. S2, C–F) that are defective in CI-MPR binding (Fig. 1). These results indicate that the interaction between CI-MPR and AP-1 through μ 1A is crucial for the normal distribution of CI-MPR at steady state.

Subsequently, we conducted RNAi to specifically knock-down (KD) γ 2 (Fig. 2A). Similar to what was observed in μ 1A KO cells (Fig. S1G), the KD of γ 2 does not appear to affect the overall levels of CI-MPR (Fig. 2, A). However, it does result in an altered steady-state distribution of CI-MPR. Compared to control cells, γ 2 depletion led to a more dispersed pattern for CI-MPR and a reduced colocalization with the Golgi marker Manosidase II-Venus (56, 57) (Fig. 2, B–D).

To further confirm this phenotype, we generated a γ 2 KO HeLa cell line using CRISPR/Cas9 (Fig. 2E) and subsequently rescued γ 2 expression in these cells using a doxycycline-inducible piggyBac transposon-based expression system (58) (referred to as γ 2 KO + γ 2 cells; Fig. S3). By employing this system, we successfully attained comparable levels of exogenous γ 2 protein and a similar subcellular distribution pattern in γ 2 knockout (KO) cells as that observed in WT cells using a doxycycline concentration of 1 ng/ml (+Dox) (Fig. S3A). This doxycycline concentration was consistently applied in subsequent experiments. Importantly, the ablation of γ 2 did not impact the total levels or subcellular distribution of γ 1 (Figs. 2E and S3, B–E). Similar to the observations in γ 2 KD cells, depletion of γ 2 in KO cells resulted in dispersed labeling of CI-MPR in cytoplasmic puncta and a notable decrease in its localization at the Golgi compared to WT cells (Fig. 2, F–H). However, this phenotype was rescued upon restoring γ 2 expression in doxycycline-treated γ 2 KO + γ 2 cells (Fig. 2, H and I).

The reduced juxtanuclear localization of CIMPR in γ 2 depleted cells prompted us to investigate whether γ 2 depletion affects the levels of CI-MPR at the cell surface. To address this, we utilized CD8-CI-MPR, a valuable reporter for studying CI-MPR trafficking, where the cytosolic tail of CD8 was replaced with the CI-MPR cytosolic tail (9, 59). Flow cytometry analysis showed that the depletion of γ 2 causes an approximately 1.75-fold increase in CD8-CI-MPR levels at the cell surface (Fig. S4A). This suggests that impaired recycling of internalized receptors to the Golgi may cause leakage to the plasma membrane, a possibility that was tested in subsequent experiments.

Since AP-1 γ 1 has also been implicated in the retrograde transport of CI-MPR from endosomes to the TGN (37–42), we tested whether AP-1 γ 1 and AP-1 γ 2 complexes co-depletion would lead to a stronger relocation of CD8-CI-MPR to the cell surface. To achieve this, we expressed CD8-CI-MPR in μ 1A KO HeLa cells. Flow cytometry analysis revealed that depletion of μ 1A resulted in a stronger (~2.5-fold) increase in cell surface levels of CD8-CI-MPR (Fig. S4B), a phenotype that could be reversed by transfection of μ 1A(WT)-GFP but not μ 1A(D174A)-GFP or μ 1A(W408S)-GFP mutants (Fig. S4B). Taken together these results suggest that both AP-1 γ 1 and

AP-1 γ 2 complexes independently contribute to maintaining proper CI-MPR levels at the plasma membrane.

CI-MPR exit from Golgi complex is not prevented by AP-1 γ 2 depletion

The data shown here indicates that AP-1 γ 2 participates in CI-MPR trafficking; therefore, we sought to investigate the possible pathways involved. To monitor the anterograde transport of CI-MPR from the TGN to early endosomes, we used the retention using selective hooks (RUSH) system. This approach entails fusing the protein of interest with a fluorescent protein and a streptavidin-binding peptide (SBP), allowing reversible entrapment of the chimera in the endoplasmic reticulum (ER) by co-expression of an ER resident protein fused to streptavidin (ER-hook). The reporter-SBP chimera can be released from the ER-hook upon the addition of biotin to the cells, enabling the tracking of its route through the secretory pathway in a synchronized manner (60).

In order to study CI-MPR trafficking using the RUSH system, we generated a stable HeLa cell line expressing streptavidin fused to the ER retention/retrieval sequence KDEL (61), and transfected these cells with a plasmid coding the transmembrane domain (TM) and the cytosolic tail (CT) of CI-MPR fused to mCherry, SBP, and a signal peptide for ER translocation at the N-terminus (RUSH-CI-MPR; Fig. S5A). Before biotin treatment, RUSH-CI-MPR displays a reticular pattern (0 min chase; Fig. S5B). Upon addition of biotin, RUSH-CI-MPR accumulates in the juxtanuclear region (50 min chase; Fig. S5C), and this is followed by detection of RUSH-CI-MPR in dispersed vesicles (120 min chase; Fig. S5D).

Next, we performed γ 2 KD by RNAi in cells expressing both streptavidin-KDEL and RUSH-CI-MPR. It was observed that RUSH-CI-MPR reaches the Golgi with similar efficiency in control or γ 2 KD cells (Fig. 3, A, B, and E). After 90 min of biotin addition, the absence of γ 2 did not hinder the exit of RUSH-CI-MPR from the Golgi, and it successfully reached early endosomes marked by EEA1 (Fig. 3, C, D, and F). These findings suggest that γ 2 is not essential for the effective trafficking of CI-MPR from the Golgi to early endosomes.

AP-1 γ 2 is a novel cellular factor required for CI-MPR retrograde trafficking

Following endocytosis, CI-MPR molecules are targeted to early endosomes and may follow a retrograde route to the TGN (7–12). Therefore, we investigated whether AP-1 γ 2 is required for CI-MPR retrograde transport. To this end, we performed a previously described protocol to specifically access the retrograde transport of CI-MPR, using CD8-CI-MPR as a reporter (9, 59). Internalized CD8-CI-MPR is tracked from the cell surface by incubating living cells with an anti-CD8 antibody for defined periods, before subsequently fixing the cells for immunofluorescence analysis. After 1 h of uptake, we observed that internalized anti-CD8:CD8-CI-MPR complexes have efficiently reached the Golgi in control cells (Fig. 4, A and C). However, retrieval to the Golgi was compromised in γ 2 KD




Figure 2. The depletion of γ 2 affects CI-MPR steady-state distribution. A, HeLa cells were treated twice with control siRNA or γ 2 siRNA. 24 h after the second treatment, cell lysates were analyzed by Western blot. HeLa control siRNA (B) or γ 2 KD (C) were transfected with a vector encoding α -ManII-Venus (green channel). After 16 h of transfection, cells were fixed and stained for CI-MPR (red channel). Scale bars: 10 μ m. D, scatter plot represents the mean \pm SD (n = 5) of Manders' co-localization coefficient between the CI-MPR signal overlapping with the α -ManII-Venus signal. * p = 0.0179; (Two-tailed paired t test). HeLa WT cells and γ 2 KO cells were analyzed by either Western blot (E) or immunofluorescence (F and G). HeLa WT cells (F), and HeLa γ 2 KO cells (G) and γ 2 KO + γ 2 cells (H) were fixed, permeabilized and stained for CI-MPR (red channel) and Giantin (green channel). Scale bars: 10 μ m. I, scatter plot represents the mean \pm SD (n = 5) of the Manders' co-localization coefficient of the Giantin signal overlapping with the CI-MPR signal for each condition. ** p = 0.0022; *** p = 0.0002; n.s. = not significant (Two-tailed paired t test).

cells, with retention of anti-CD8:CD8-CI-MPR complexes in early endosomes labeled by HRS (Fig. 4, B and D).

The γ 2-dependent retrieval of CD8-CI-MPR from early endosomes to the Golgi was confirmed in γ 2 KO and γ 2 KO +

inducible γ 2 cells (Fig. 4, E–I). Even after a 3-h uptake period, the colocalization of CD8-CI-MPR with ManII-Venus stays consistently lower in γ 2 KO cells compared to the control, while colocalization with HRS remains higher (Fig. S6).

CI-MPR and ATP7B retrograde transport requires AP-1 γ 2




Figure 3. The depletion of γ 2 does not affect CI-MPR exit from the Golgi complex. HeLa cells expressing an ER-Hook (streptavidin-KDEL) were treated with siRNA control (A and C) or γ 2 siRNA (B and D) and transfected with RUSH-CI-MPR and α -ManII-Venus plasmids. After 16 h, cells were incubated with soluble biotin and fixed at different time points to follow RUSH-CI-MPR anterograde transport. Panel A and B represents cells fixed 30 min after biotin addition and Panel C and D represents the effects after 120 min of biotin addition. After fixation, cells were immunostained for EEA1 (cyan channel). Scale bars: 10 μ m. E and F, the graphs represent the mean \pm SD ($n \geq 5$) of Manders' co-localization coefficients of the RUSH-CI-MPR signal overlapping with the α -ManII-Venus signal (E) or with the EEA1 signal (F) during different time points after soluble biotin treatment.

Therefore, prolonged retention of endocytosed CD8-CI-MPR in early endosomes in γ 2 KO cells is likely due to a blockade in retrograde transport rather than a trafficking delay. Impairment of endosome-to-Golgi retrieval of endocytosed CD8-CI-MPR was also observed and appeared stronger in μ 1A KO cells (Fig. S7). The data supports previous reports that μ 1A functions in MPR retrograde transport (39, 40), and is consistent with the notion that both AP-1 γ 1 and AP-1 γ 2 complexes individually contribute to CI-MPR retrograde transport.

Altogether, our data indicate a critical role of AP-1 γ 2 in the CI-MPR retrograde pathway that AP-1 γ 1 does not compensate for. To investigate this further, we asked if the overexpression

of γ 1 can suppress the retrograde trafficking defect caused by γ 2 depletion. Initially, we assessed the maximum level of exogenous γ 1 expression (γ 1-Venus) to be employed in these assays, ensuring that it does not result in mislocalization. At low expression levels (0.5 μ g of coding vector), γ 1-Venus displayed a punctate pattern that was mostly juxtanuclear, and similar to the distribution pattern of endogenous γ 1 in untransfected cells (Fig. 5, A and B). At higher expression levels (1.0 and 1.5 μ g of coding vector) γ 1-Venus appear gradually more dispersed (Fig. 5, C and D). Hence, we utilized intermediate concentrations (1.0 μ g) of the γ 1-Venus coding vector for uptake experiments in γ 2 KO cells. The results




Figure 4. Efficient CI-MPR retrieval from early endosomes to the Golgi complex requires $\gamma 2$. HeLa cells were treated with siRNA control (A) or siRNA $\gamma 2$ (B) and then transfected with CD8-CI-MPR and α -ManII-Venus (green channel) plasmids. After 16 h, cells were used for anti-CD8 antibody uptake assay for 1 h (red channel), and then fixed and permeabilized for HRS staining (cyan channel). Scale bars: 10 μ m. C and D, scatter plot represents the mean \pm SD (n = 5) of Manders' co-localization coefficients of the CD8-CI-MPR signal overlapping with the α -ManII-Venus signal (C) or the HRS signal (D) for each condition. $***p < 0.0001$ (C); $***p = 0.0003$ (D); (Two-tailed paired t test). HeLa WT cells (E), HeLa $\gamma 2$ KO cells (F) or HeLa $\gamma 2$ KO cells expressing exogenous $\gamma 2$ in an inducible manner (+i $\gamma 2$) (G) were transfected with CD8-CI-MPR and α -ManII-Venus (green channel) plasmids and used for anti-CD8 uptake (red channel) assays for 1 h. Cells were fixed and permeabilized for HRS staining (cyan channel). Scale bars: 10 μ m. H and I, scatter plot represent the mean \pm SD (n = 7) of Manders' co-localization coefficients of the CD8-CI-MPR signal overlapping with the α -ManII-Venus signal (H) or the HRS signal (I) for each condition. $***p < 0.0001$; n.s. = not significant (Two-tailed paired t test).

showed that $\gamma 1$ expression does not restore the CD8-CI-MPR retrograde trafficking defect induced by $\gamma 2$ depletion (Fig. 5, E–G), thereby confirming that AP-1 $\gamma 2$ and AP-1 $\gamma 1$ are not functionally redundant.

In AP-1 $\gamma 2$ KO cells, endocytosed CI-MPR is sequestered in endosomes that exhibit enrichment of retromer subunits

One of the most extensively studied machineries responsible for CI-MPR retrograde transport is the retromer complex (9, 12, 62). A previous study showed that endocytosed CD8-CI-MPR transiently colocalizes with the retromer subunit Vps26 in endosomes en route to the Golgi (9). To gain insights into the interplay between the retrograde transport steps mediated

by retromer and AP-1 $\gamma 2$, we stained endogenous retromer subunits in AP-1 $\gamma 2$ knockout (KO) cells during CD8-CI-MPR internalization experiments.

In control cells, staining of Vps26 (Fig. 6, A–C) and Snx2 (Fig. 6, D–F), another retromer subunit, shows a discrete punctate pattern dispersed throughout the cytoplasm, and display relatively low colocalization with internalized CD8-CI-MPR after 2 h of uptake (Fig. 6, C and F). In $\gamma 2$ KO cells, internalized CD8-CI-MPR shows a much higher colocalization with Vps26 (Fig. 6, A–C) and Snx2 (Fig. 6, D–F), which are enriched in larger vesicular structures. This suggests that CD8-CI-MPR resides for an extended period in retromer-positive domains of endosomes, implying that AP-1 $\gamma 2$ influences the retromer dynamics.

CI-MPR and ATP7B retrograde transport requires AP-1 γ 2




Figure 5. Overexpressing exogenous γ 1 in γ 2 KO cells does not recover CD8-CI-MPR retrograde transport. A–D, heLa WT cells untransfected (A) or transfected with 0.5 μ g (B), 1.0 μ g (C) or 1.5 μ g (D) of vector coding for γ 1-Venus (green channel). After 16 h, cells were fixed and permeabilized for γ 1 staining (red channel). Note that γ 1 is mislocalized upon transfection of 1.5 μ g of vector coding for γ 1-Venus. Scale bars: 10 μ m. HeLa WT cells (E) and HeLa γ 2 KO cells (F) were transfected with CD8-CI-MPR and 1 μ g of γ 1-Venus (green channel) plasmids. After 16 h, cells were used for anti-CD8 antibody uptake assay for 2 h (red channel), and then fixed and permeabilized for HRS staining (cyan channel). Scale bars: 10 μ m. G, scatter plot represent the mean \pm SD (n = 5) of Mander's co-localization coefficients of the CD8-CI-MPR signal overlapping with the HRS signal for each condition. ***p = 0.0003. Two-tailed paired t test.

ATP7B retrograde transport requires AP-1 γ 2

To further explore the involvement of AP-1 γ 2 in retrograde trafficking from endosomes to the Golgi complex, we investigated the trafficking of the copper transporter ATP7B, known to rely on AP-1 (37, 44, 45, 47). Previous studies demonstrated the interaction of ATP7B with AP-1 (44, 45, 47). Co-immunoprecipitation assays using GFP-Trap showed the

interaction of both γ 1 and γ 2 with GFP-ATP7B (Fig. 7A), suggesting that either AP-1 variant can bind ATP7B.

The interaction between ATP7B and AP-1 γ 2 prompted us to investigate the role of this AP-1 variant in ATP7B intracellular trafficking. To track ATP7B trafficking, we transfected GFP-ATP7B into HeLa WT, γ 2 KO, or γ 2 KO + γ 2 cells (Fig. 7, B–K). Under copper-limiting conditions (+BCS), GFP-




Figure 6. Depletion of γ 2 leads to retention of internalized CD8-CI-MPR in endosomes positive for Retromer complex subunits. HeLa WT cells (A and D) and HeLa γ 2 KO cells (B and E) were transfected with a CD8-CI-MPR plasmid. After 16 h, cells were used for an anti-CD8 antibody uptake assay for 2 h (red channel), and then fixed and permeabilized for Vps26 (A and B) or Snx2 (D–E) staining (green channel). Scale bars: 10 μ m. Scatter plot represent the mean \pm SD (n = 5) of Mander's co-localization coefficients of the CD8-CI-MPR signal overlapping with the Vps26 (C) or Snx2 (F) signals for each condition. *** p < 0.0001 (C); *** p = 0.0005 (F) (Two-tailed paired t test).

ATP7B predominantly localized to the juxta nuclear region, colocalizing with the Golgi marker GM130 in all three cell lines (Fig. 7, B–D, and K). In contrast, high levels of Cu⁺ (200 μ M) resulted in the redistribution of GFP-ATP7B from the Golgi complex to the cell surface, reducing its colocalization with GM130 (Fig. 7, E–G, and K).

Consistent with the findings from RUSH-CI-MPR (Fig. 3), the depletion of γ 2 did not affect the egress of GFP-ATP7B from the Golgi complex (Fig. 7F), suggesting that AP-1 γ 2 may not be involved in this anterograde pathway. Importantly, after copper washout, GFP-ATP7B relocated from the cell surface back to the Golgi complex (Fig. 7, H and K), a process impaired in γ 2 KO cells (Fig. 7, I and K), but rescued by the induced expression of γ 2 (Fig. 7, J and K). Overall, these results support the requirement of AP-1 γ 2 for ATP7B retrograde trafficking.

Discussion

Our study provides compelling evidence that the γ 2-adaptin is an integral component of a functional AP-1 complex variant, serving as novel sorting machinery that regulates the trafficking of both CI-MPR and ATP7B, and that is not functionally compensated by γ 1. Specifically, we establish the crucial role of AP-1 γ 2 in mediating the retrograde transport of transmembrane receptors from the endosomal system back to the TGN. While previous studies have implicated AP-1 in the bidirectional transport of CI-MPR between the TGN and endosomes (34–42), these investigations focused on perturbing the μ 1 and/or γ 1 subunits, without exploring the involvement of the γ 2 isoform. Our findings shed new light on the functional significance of a poorly characterized variant of AP-1 in these critical transport processes.

CI-MPR and ATP7B retrograde transport requires AP-1 γ 2




Figure 7. GFP-ATP7B interacts with AP-1 γ 1 or AP-1 γ 2 and its retrieval to the TGN requires AP-1 γ 2. A, PEAK cells expressing GFP or GFP-ATP7B were treated for 2 h with 200 μ M CuCl₂ and the cleared cell lysates were subjected to GFP-Trap Co-IP assay and Western blot for GFP, γ 2 and γ 1. Western blot of β -actin was used as a negative control. Input represents 2% of cell lysates used in the GFP-Trap Co-IP assay. HeLa WT cells (B, E, and H) and HeLa γ 2 KO cells (C, F, and I) and γ 2 KO + γ 2 cells (D, G, and J) expressing GFP-ATP7B were treated with BCS (B–D), CuCl₂ (E–G) and CuCl₂ + BCS (H–J) and then fixed and permeabilized for GM130 staining (green channel). Scale bars: 10 μ m. K, scatter plot represent the mean \pm SD (n = 5) of Mander's co-localization coefficients of the GM130 signal overlapping with the GFP-ATP7B signal for each condition. *** $p < 0.005$ *** $p < 0.0005$. n.s. = not significant (one-way ANOVA with Bonferroni's corrections).

Our initial experiments demonstrated the interaction of CI-MPR with both AP-1 γ 1 and AP-1 γ 2 complexes (Fig. 1). Utilizing yeast two-hybrid and Co-IP assays, we confirmed that CI-MPR directly binds to the μ 1 subunit. Additionally, we established that the conserved YXX Φ motif in the cytosolic tail of CI-MPR (₂₃₅₃YSKV₂₃₅₆) is responsible for its interaction with μ 1A, specifically through the tyrosine binding pocket. While the binding of μ 1A-(WT)-GFP to γ 1 or γ 2 subunits does not rely on the integrity of the tyrosine binding pocket, our experiments with mutants in this region of μ 1A revealed a decreased ability to capture (Fig. 1) and transport (Fig. S2) CI-MPR, indicating that the interaction with μ 1A is crucial for stabilizing the CI-MPR complex with AP-1.

To further support the involvement of γ 2-adaptin in an AP-1 complex variant, we investigated the stability and subcellular distribution of γ 2 in μ 1A KO cells. Consistent with our previous findings (51, 52), we observed a significant reduction in the levels of γ 2 and the loss of its punctate distribution pattern in μ 1A KO cells (Fig. S1). Notably, the levels of γ 2 and its subcellular distribution were restored when exogenous μ 1A-GFP WT or μ 1A-GFP tyrosine binding pocket mutants were expressed in μ 1A KO cells. Similar results were also observed for γ 1 (Fig. S1), indicating that the stability and localization of both γ 1 and γ 2 are dependent on the presence of μ 1A.

Before investigating the specific role of AP-1 γ 2 in CI-MPR distribution, we used μ 1A KO cells to examine the effects of AP-1 γ 1 and AP-1 γ 2 co-depletion. In line with the established role of μ 1A in the retrieval of CI-MPR from endosomes to the Golgi (39), CI-MPR localization shifted from a perinuclear to a more dispersed punctate pattern in μ 1A KO cells (Fig. S2). Moreover, μ 1A KO cells misdirected a CD8-CI-MPR chimera to the plasma membrane (Fig. S4). These effects are likely to be direct consequences of AP-1 function in CI-MPR trafficking itself, since expression of μ 1A mutants able to form complexes with the γ -subunits, but that does not bind CI-MPR efficiently, are unable to rescue the defective sorting phenotypes, in contrast to exogenous μ 1A WT expression (Figs. S2 and S4).

The specific depletion of AP-1 γ 2 resulted in a dispersed intracellular distribution of endogenous CI-MPR compared to control cells (Fig. 2). This phenotype was confirmed by γ 2 RNAi and KO/rescue strategies and is consistent with previous studies linking dispersed CI-MPR localization to impaired endosome-to-TGN sorting (63–65). Further supporting this notion, the retrieval of CD8-CI-MPR from endosomal compartments to the Golgi complex was compromised in AP-1 γ 2-depleted cells, as the internalized reporter construct failed to reach the Golgi and instead accumulated in early endosomes that contain HRS (Figs. 4 and 5) and retromer subunits (Fig. 6). These findings suggest that AP-1 γ 2 may play a broader role in the retrograde pathway. This is further supported by the observation that GFP-ATP7B, a cargo known to require AP-1 for retrograde trafficking, failed to return from the cell surface to the Golgi complex in γ 2 knockout cells and instead became trapped in endosomes (Fig. 7).

Significantly, the missorting phenotypes of CI-MPR observed in μ 1A KO cells (Figs. S2 and S6), where both γ 1 and γ 2 are depleted, were stronger than those observed when

γ 2 alone is lacking (Figs. 2 and 4). However, the observed partial impairment in retrograde trafficking in γ 2 KO cells does not solely arise from a reduction in the overall concentration of either AP-1 variant. This conclusion is supported by the fact that augmenting the intracellular levels of γ 1 in these cells through exogenous expression did not restore the retrograde trafficking defect caused by γ 2 depletion (Fig. 5).

Previous data suggest that AP-1 γ 1 mediates the anterograde transport of MPRs in cooperation with GGAs (Golgi-localized, γ -adaptin ear-containing, Arf-binding) adaptors (37, 66, 67). In addition, the interaction of ATP7B with AP-1 γ 1 has been shown to affect ATP7B localization at the TGN (44, 45, 47). Interestingly, our findings indicate that the depletion of AP-1 γ 2 does not impair the efficient exit of CI-MPR and ATP7B from the Golgi complex, as observed in synchronized anterograde trafficking assays (Figs. 5 and 7). Furthermore, while AP-1 γ 1 is crucial for sorting cargo proteins to the basolateral and apical membranes in polarized cells, AP-1 γ 2 appears to have distinct functions (68). In conclusion, our study contributes to a growing body of evidence showing that AP-1 γ 1 and AP-1 γ 2 are not merely redundant AP-1 complexes (69).

Why does AP-1 γ 2 depletion compromise CI-MPR and ATP7B retrograde transport? Clathrin and clathrin-related adaptor proteins have previously been implicated in endosome-to-TGN trafficking. Monomeric adaptor proteins, such as epsinR and GGAs, have been shown to facilitate the retrieval of cargo proteins from endosomes (46, 70–72). Moreover, the μ 1 and γ 1 subunits of AP-1 have been implicated in the retrograde pathway of CI-MPR (37, 41, 42) and ATP7B (37, 47, 73) from endosomes to the TGN. Therefore, the depletion of AP-1 γ 2 may disrupt the recruitment of clathrin and its adaptors to specific subdomains of endosomes involved in retrograde transport, leading to impaired CI-MPR and ATP7B transport from these organelles.

We propose that both AP-1 γ 1 and AP-1 γ 2 variants play independent roles in facilitating the proper transport of CI-MPR and ATP7B from the endosomal system back to the Golgi complex. Cargo proteins employ multiple sorting machinery elements to achieve accurate membrane localization within the endo-lysosomal system. However, how these different sorting machinery components are organized, and their functions coordinated to perform the endosome-to-TGN transport remains a subject of debate (63–65, 74). The retromer complex is the most extensively studied sorting machinery involved in retrograde endosome-to-TGN trafficking, acting as a transport carrier coat and as a central hub that recruits diverse molecules to early endosomes (75–77).

A previous study suggested that clathrin and retromer act in two successive steps of the same retrograde pathway from endosomes to the TGN (78). According to this model, the recruitment of clathrin onto maturing early-endosomal microdomains is necessary to initiate membrane-curvature changes, ultimately leading to tube formation. This process is essential for the efficient retromer-mediated transport to the TGN. Our findings align with this model and indicate that the function of AP-1 γ 2 influences retromer dynamics. In cells lacking AP-1 γ 2, the internalized CD8-CI-MPR fails to reach

CI-MPR and ATP7B retrograde transport requires AP-1 γ 2

the Golgi; instead, it accumulates in enlarged endosomes enriched for VPS26 and SNX2 (Fig. 6), suggesting that AP-1 γ 2 and retromer are involved in sequential trafficking step within the same transport pathway. In this context, a systematic investigation into whether and how AP-1 γ 2 influences the localization of Rab proteins involved in specific trafficking pathways between endosomes and the TGN (79, 80) may offer invaluable additional insights into AP-1 γ 2 function in these processes.

The physical proximity of the retromer complex to clathrin-coated structures at endosomes has been reported, and retromer complex subunits have been found in CCV preparations (78, 81–83). On the other hand, the retromer subunits and clathrin are present in distinct transport intermediates, and there is no evidence of direct interaction between clathrin/adaptors and retromer subunits (84, 85). In this scenario, ESCPE-1, a membrane-tubulating complex formed by heterodimers of SNX1 or SNX2 and SNX5 or SNX6, was also shown to facilitate endosome to TGN transport of CI-MPR independently of retromer (86, 87). Intriguingly, μ 1 (Fig. 1) and the SNX5/SNX6 subunit of ESCPE-1 (88) bind to partially overlapping regions of the CI-MPR tail. Therefore, unraveling whether these molecules and complexes function independently or collaboratively and whether they act concurrently or sequentially remains challenging in the field.

The accumulation of CI-MPR and ATP7B in endosomes upon AP-1 γ 2 depletion could also be attributed to its proposed role in endosomal maturation through interactions with subunits of the Endosomal Sorting Complex Required for Transport (ESCRT) machinery (50). Specifically, AP-1 γ 2, but not AP-1 γ 1, is crucial for the efficient targeting of the EGF:EGFr complex to the canonical multivesicular bodies (MVBs) pathway (49–51). In addition, AP-1 γ 2 is utilized by HIV-1 Nef to retain CD4 and MHC-1 in endosomes and promote their lysosomal degradation (51, 52), which is known to involve targeting to MVBs (89, 90). These observations suggest that AP-1 γ 2 plays a unique role on endo-lysosomal function and trafficking processes.

Experimental procedures

Plasmids

For yeast two-hybrid assays, the plasmids containing the full-length sequences of mouse μ 1A and its D174A and W408S mutants, mouse μ 2, rat μ 3A, human μ 4 and the C-terminal domain of human μ 1B (residues 137–423), subcloned in the pACT2 vector in fusion with the Gal4-activation domain (AD) (Clontech) have been described previously (54, 91). The CI-MPR cytosolic tail (last 164 amino acids) was subcloned from the pB42AD vector (12, 92) into the pBridge vector (Clontech), and the pBridge-CI-MPR_CT(Y26A) was generated in this study by site-directed mutagenesis (QuickChange - Agilent) and was verified by sequencing. The cytosolic tails of TGN38 and LAMP-2a were subcloned in fusion with the Gal4-binding domain (BD) in the vectors pGBT9 and pBridge, respectively (29, 31). The plasmid used to express μ 1A-GFP was previously described (91) and encodes a GSGSGGS

GSGRDPPVAT amino acid linker between the μ 1A and GFP sequences. The plasmid used to express GFP-ATP7B was previously described (45). All of the above plasmids were kindly donated by Juan Bonifacino (NICHD, NIH). The plasmid to express γ 1-Venus was obtained by subcloning the human γ 1 coding sequence into the *XhoI/BamHI* restriction sites of pVenus-N1 vector (Clontech), resulting on a RDPVAT amino acid linker between the γ 1 and Venus sequences. The plasmid for α -ManII-Venus was kindly donated by George Patterson and was previously described (56). The coding sequence for IL-2s.s.-SBP-mCherry was amplified by PCR from the mCherry-APP-GFP RUSH bicistronic vector (93) and inserted into the *NheI/EcoRI* sites of the pCI-neo vector (Promega; here after named pCI-neo_RUSH). Then, the coding sequence for the transmembrane and cytosolic tail of CI-MPR was amplified by PCR from the GFP-CIMPR construct, kindly donated by Juan Bonifacino, and cloned in frame with IL-2s.s.-SBP-mCherry at *EcoRI/SalI* of the pCI-neo_RUSH, resulting in the RUSH-CI-MPR construct used in the experiments. To allow inducible expression of γ 2 in HeLa cells using a piggyBac transposon-based mammalian cell expression system (58), the human coding sequence for γ 2 was amplified by PCR from the pGADT7_ γ 2 (51) and inserted into the *NheI/HindIII* sites of the PB-TSW vector, resulting in the PB-T γ 2 construct. The original PB-TSW, a generous gift from Dr Stephen Graham (University of Cambridge), is derived from PB-T-PAF (58) after the insertion of a woodchuck hepatitis virus (WHV) posttranscriptional regulatory element (WPRE) at the 3' end. The pF5A_PBase plasmid encoding the piggybac transposase (PBase) was also generated by Dr Stephen Graham by subcloning the PBase sequence from pPBase (58), into the pF5A vector from Promega. The PB-RN plasmid carrying the reverse tetracycline transactivator (rtTA) inducer and the neomycin resistance gene was previously described (58). The construct coding the cytoplasmic tail of CIMPR fused to the extracellular and transmembrane domains of CD8 (CD8-CI-MPR) was a kind gift from Matthew Seaman, University of Cambridge (9).

Yeast two-hybrid assay

Yeast two-hybrid assays were performed using the yeast AH109 reporter strain as described previously (51). Yeast containing both plasmids with Gal4 Activation Domain (AD) or Binding Domain (BD) was selected in a medium without tryptophan and leucine. Protein interactions were determined by yeast growth in a selective medium lacking leucine, tryptophan, and histidine.

Immunoprecipitation assay of endogenous CI-MPR

Immunoprecipitation assays were performed as previously described (94). Briefly, HeLa cells were lysed with PBS-T (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.76 mM KH₂PO₄, and 0.1% [vol/vol] Triton X-100 [Sigma-Aldrich], pH 7.4; supplemented with a protease inhibitor cocktail) on ice for 20 min and then clarified by centrifugation at 14,000g for 20 min at 4 °C. Next, cell lysate was precleared with protein

G-Sepharose (17–0618–01; GE Healthcare) beads for 2 h at 4 °C under orbital agitation. Precleared lysates were recovered and incubated with mouse CD4 antibody (MHCD0400–4; Invitrogen) or mouse CI-MPR antibody (Ab2733; Abcam) for 2 h followed by a further 2 h incubation with protein G-Sepharose beads, under orbital agitation at 4 °C. The samples were then washed five times in PBS-T and the immunoprecipitated complexes were eluted with sample buffer [SDS 4%, Tris-HCl 160 mM (pH 6.8), glycerol 20%, DTT 100 mM and 0.005% Bromphenol Blue] and used for SDS-PAGE and Western blot analysis.

GFP-Trap Co-IP assay

GFP-Trap agarose (ChromoTek) assays were performed following the manufacturer's recommendations. Briefly, 85% confluent PEAK cells placed in a 100 mm plate were transfected with vectors to express GFP, AP-1 μ 1A(WT)-GFP, AP-1 μ 1A(D174A)-GFP or AP-1 μ 1A(W408S)-GFP by using 30 μ l of 25-kDa linear PEI (1-mg/ml stock solution). After 16 h, cells were resuspended in lysis buffer [10 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% Nonidet P40, supplemented with a protease inhibitor cocktail (P8340; Sigma-Aldrich)] and centrifuged at 14,000g for 20 min at 4 °C. Protein levels in the clarified cell lysates were quantified using the Bio-Rad's Bradford protein assay (Biorad) to equalize total protein levels. Equal amounts of proteins were incubated with GFP-Trap beads for 2 h at 4 °C while rotating. Next, beads with bound proteins were washed 5 times with washing buffer [10 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.5 mM EDTA], eluted with sample buffer [160 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 100 mM DTT and Bromphenol Blue 0.005%], boiled, and analyzed by SDS-PAGE and Western blot. For GFP-ATP7B Co-IP assay, a protocol was adapted from the previous work of Lalioti *et al.* (44). Briefly, 85% confluent PEAK cells placed in two 100 mm plates were transfected with vectors to express GFP or GFP-ATP7B by using 30 μ l of 25-kDa linear PEI (1 mg/ml stock solution). After 20 h, cells were incubated with 200 μ M CuCl₂ for 2 h at 37 °C. After this period, cells were resuspended with lysis/wash buffer [20 mM HEPES pH 7.5, 250 mM Sucrose, 0.1% Nonidet P40, 130 mM NaCl, 1 mM EDTA, 1 mM Sodium Orthovanadate, 50 mM Sodium Fluoride, 100 mM Sodium pyrophosphate, supplemented with a protease inhibitor cocktail (P8340; Sigma-Aldrich)] and centrifuged at 14,000g for 20 min at 4 °C. Protein levels in the clarified cell lysate were quantified using Bio-Rad's Bradford protein assay (Biorad) to equalize total protein levels. Equal amounts of proteins were incubated with GFP-Trap beads overnight at 4 °C while rotating. Next, beads with bound proteins were washed 5 times with lysis buffer/wash buffer and then eluted with the sample buffer described above, boiled, and analyzed by SDS-PAGE and Western blot.

Cell culture, transfections, and siRNA

PEAK cells (HEK-293T cells transfected with the large T antigen of SV-40) were grown as previously described (95). HeLa AP-1 μ 1A CRISPR/Cas9 KO and HeLa WT cells were a

gift from Margaret S. Robinson (University of Cambridge) and have been previously described (55). Cells were expanded, frozen as aliquots and stored in vapor phase liquid nitrogen. The aliquots were used up to the 15th passage and discarded. PCR tests for *mycoplasma* were negative. For RNA interference assays, HeLa cells were subjected to two rounds of siRNA transfection with a 48 h interval, using the Oligofectamine reagent (Thermo Scientific). The siRNAs were purchased from Dharmacon as nucleotide duplexes with 3'dTdT overhangs, designed to target human AP-1 γ 2 (5'-AAACCCUGCUUUG-CUGUUA-3') (51). In the control experiments, the MISSION siRNA Universal Negative Control (SIC001, Sigma-Aldrich) was used. Cells were harvested for the assays 4 days after the first siRNA transfection. Alternatively, at day 4, cells were transfected with plasmids DNA using Lipofectamine 2000 (Thermo Scientific) and analyzed on day 5.

Generation of γ 2 KO cells by CRISPR/Cas9 and γ 2 KO cells rescued for γ 2 expression

The identification of a gRNA target in exon 1 (5'-CCTCATCGAAGAGATTTCGCG-3') of the AP1G2 gene was performed by using the Zhang online CRISPR design tool (<http://crispr.mit.edu/>) (96). The gRNA was ordered as a pair of complementary oligonucleotides (Sigma-Aldrich) with the sequences 5'-CACCGN20 to 3' and 5'-AAACN20C-3', annealed and cloned into the *Bbs*I site of the pX330 vector (Addgene), which expresses both Cas9 and gRNA. HeLa cells were transfected with pX330 and pIRESpuro (Clontech) in a ratio of 3:1 using the TRANSIT-HeLaMONSTER transfection kit (MIR 2900; Mirus Bio). After 2 days, cells were treated with Puromycin for 3 days and single-cell clones were isolated by serial dilution and tested for γ 2 KO by Western blot and immunofluorescence assays. To generate γ 2 KO cells rescued for γ 2 expression (termed γ 2 KO + γ 2 cells), we transfected the PB-T γ 2, PB-RN, and pF5A_PBase in γ 2 KO cells (ratio 5:1:1) by using Lipofectamine 2000 (Thermo Scientific). After 16 h post-transfection, cells were treated with Puromycin (P8833; Sigma-Aldrich) and Geneticin (11,811–031; Gibco) for 1 week and different concentrations of Doxycycline (D9891; Sigma-Aldrich) were tested to induce γ 2 expression.

Antibodies

The mouse anti-CI-MPR antibody (Ab2733; Abcam) and rabbit anti-CI-MPR antibody (ab124767; Abcam) were used for immunofluorescence and Western blot, respectively. The antibodies for Giantin (924,302; Convance), HRS (ab155539; Abcam), GM130 (610,822; BD Biosciences) and EEA1 (610,456; BD Biosciences) were used for immunofluorescence. The antibodies for γ 1 (610,386; BD Biosciences), γ 2 (HPA004106; Sigma-Aldrich), μ 1A (AB111135; Abcam), GAPDH (G9545; Sigma-Aldrich) and β -actin (sc-47778; Santa Cruz) were used for Western blot. The same antibodies for γ 1 and γ 2 were also used for immunofluorescence. The rabbit anti-Vps26 and anti-Snx2 anti-serum were kind gifts from Juan Bonifacino, and previously described (97, 98). The rabbit anti-GFP antibody used for western-blot was a gift from R.

CI-MPR and ATP7B retrograde transport requires AP-1y2

Hegde (MRC). The mouse monoclonal anti-CD8 antibody used for flow cytometry and antibody uptake assays was a kind gift from Matthew Seaman (MRC) (9). Horseradish-peroxidase-conjugated donkey anti-mouse immunoglobulin G (IgG) and donkey anti-rabbit IgG were obtained from GE Healthcare. Secondary antibodies conjugated to Alexa fluorophores were purchased from Thermo Scientific.

Anti-CD8 antibody uptake assay

The anti-CD8 antibody uptake assay was performed as previously described (9, 59, 94). Briefly, HeLa cells expressing CD8-CI-MPR were washed 3 times with PBS and incubated with Opti-MEM for 30 min at 37 °C. Then, cells were incubated for 1h to 3h (see Figure legends) continuously with the anti-CD8 antibody (1 µg of anti-CD8 antibody in DMEM), depending on the experiment, as described in the Figure legends. Cells were washed 3 times with PBS, fixed with PFA 4% in PBS, and processed for immunofluorescence as described below.

Retention using selective hooks (RUSH) assay and immunofluorescence microscopy

HeLa cells transfected with vectors coding for ER-hook and RUSH-CI-MPR were processed for single cell sorting by the Becton Dickinson FACS Aria Fusion (Center for Cell-Based Therapy/Hemocentro de Ribeirão Preto) selecting cells positive for the mCherry signal. mCherry-positive cells were grown under puromycin and G418 treatment and individual clones were used in RUSH assays. Cells were treated with 40 µM of soluble Biotin (pulse) and incubated for different time points (chase) prior to fixation. Immunofluorescence was performed as previously described with no modifications (99). Cells were imaged on a Zeiss confocal laser-scanning microscope (LSM) 780 (Zeiss). Post-acquisition image processing and colocalization analysis were as previously described (51).

GFP-ATP7B trafficking assay

The GFP-ATP7B trafficking assay was adapted from previous work from Jain and colleagues (45). Briefly, HeLa WT cells, γ2 KO cells and γ2 KO + iy2 cells were grown on coverslips and transfected with pGFP-ATP7B using Lipofectamine 2000 (Thermo Scientific). After 16 h post transfection, cells in DMEM media were treated as follow: (1) cells treated with Cu⁺⁺-chelator bathocuproinedisulfonic acid (BCS) only - cells were incubated with 50 µg/ml cycloheximide and 200 µM BCS for 4 h at 37 °C (medium was replaced every 2 h); (2) cells treated with CuCl₂ only - cells were treated with 50 µg/ml cycloheximide and 200 µM CuCl₂ for 2 h; (3) cells treated with CuCl₂ and BCS (copper washout) - cells were treated first with 200 µM CuCl₂ for 2 h, and then with 200 µM BCS for further 4 h, always in the presence of 50 µg/ml cycloheximide (medium was replaced every 2 h).

SDS-PAGE and Western blot analysis

Total cell lysates were prepared and equalized for total protein concentration, as previously described (51). Briefly,

protein homogenates were mixed with sample buffer [160 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 100 mM DTT, and 0.005% Bromphenol Blue], boiled, and subjected to SDS-PAGE and electrotransferred to a nitrocellulose membrane (Millipore, Bedford, MA, USA). The membranes were blocked with PBS-T (PBS, 05% Tween 20) and 5% nonfat dry milk for 1 h at room temperature, followed by individual incubation with primary antibodies in PBS + 1% BSA overnight at 4 °C under gentle agitation. After that, the membranes were washed 5 times with PBS-T and incubated with secondary antibodies conjugated to horseradish peroxidase (HRP) (GE Healthcare) in PBS-T (PBS, 05% Tween 20) and 5% nonfat dry milk for 1 h at room temperature. The membranes were washed five times with PBS-T and proteins were detected using enhanced chemiluminescence solutions [solution 1: 1 M Tris-HCl (pH 8.5), 250 mM luminol, 90 mM p-coumaric acid; and solution 2: 30% H₂O₂, 1 M Tris-HCl (pH 8.5)] and visualized with the ChemiDoc imaging system (GE Life Science).

Immunofluorescence and confocal assays

Immunofluorescence was performed, as previously described (51). Briefly, cells were grown overnight on glass coverslips, then fixed with 4% (wt/vol) paraformaldehyde (PFA) in PBS for 15 min at room temperature. Fixed cells were permeabilized/blocked with blocking solution [0.01% (wt/vol) Saponin (S7900; Sigma-Aldrich), 0.2% [wt/vol] pork skin gelatin (G2500; Sigma-Aldrich) in PBS] for 15 min at 37 °C. Next, cells were incubated with primary and, subsequently, with secondary antibodies for 1 h at 37 °C in blocking solution. Coverslips were mounted on slides with Fluoromount-G Mounting Medium (17,984–25; Electron Microscopy Sciences), and cells were imaged on a Zeiss confocal laser scanning microscope (LSM) 780 (Zeiss, Jena, Germany). Post-acquisition image processing was performed with ImageJ 1.36 (100). Colocalization analyses were performed with sets of images of the same cells (Z-stack) for each marker. Quantification was performed with ImageJ and the plug-in Co-localization Threshold to determine the Mander's coefficients (tM) for each channel.

Flow cytometry analysis

To assess the levels of surface CD8-CI-MPR, unfixed cells were incubated for 30 min at 4 °C with mouse anti-CD8 antibody (9, 59) followed by incubation for 30 min at 4 °C with F(ab')₂-Goat anti-Mouse IgG (H + L) Cross-Adsorbed Secondary Antibody Alexa Fluor 647 (Cat. A21237; Thermo Scientific) in PBS supplemented with 1% BSA, and then fixed with PFA 1% in PBS + 1% BSA and subjected to flow cytometry analysis. Data were acquired using the levels of Alexa 647 fluorescence in cells from a BD LSRFortessa flow cytometer (BD Biosciences) and FACSymphony A5 Cell Analyzer (BD Biosciences) at the Ribeirão Preto Center for Cell-Based Therapy/Hemotherapy. The FloJo software (Tree Star) was used for data analyses.

Statistical analysis

All statistical data are demonstrated as mean \pm SD and the n samples are indicated in the figure legend for each analysis. Data were plotted and analyzed using GraphPad Prism 5.0 software.

Data availability

All data are contained within the article itself and/or its supporting information, which is accessible online.

Supporting information—This article contains supporting information.

Acknowledgments—We thank Juan S. Bonifacino, Mathew Seaman and Stephen Graham for the kind donation of reagents; Roberta Rosales for help with confocal microscopy in the Multiuser Laboratory of Multiphoton Microscopy Facility (FMRP-USP). We thank Patricia Palma and Camila Bonaldo for help with the flow cytometry assays in the Core Cytometry Facility at the Center for Cell-Based Therapy (Hemotherapy Center of Ribeirão Preto, University of São Paulo). We would like to extend our heartfelt gratitude to Margaret S. Robinson and Jennifer Hirst (CIMR, University of Cambridge) for their invaluable mentoring to Lucas A. Tavares and insightful discussions, which greatly contributed to the success of this work.

Author contributions—L. A. T. and L. L. P. D. conceptualization; L. A. T. and L. L. P. D. methodology; L. L. P. D. data curation; L. A. T. and L. L. P. D. writing—original draft preparation; L. A. T., R. L. R., C. S. d. C., J. A. N., J. V. d. C., and A. N. d. C. visualization; L. A. T., R. L. R., C. S. d. C., J. A. N., J. V. d. C., and A. N. d. C. investigation; L. L. P. D. supervision; L. L. P. D. funding acquisition; L. A. T. and L. L. P. D. writing—reviewing and editing.

Funding and additional information—Research in the authors' laboratory is supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation; FAPESP) grant (2019/26119–0; 2022/15928–8) and Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FAEPA) grants to L. L. P. d. S. L. A. T., R. L. R. and C. S. C. were supported by doctoral scholarships (2016/18207–9, 2019/27725–1, 2019/15280–5, respectively) from FAPESP. L. A. T. was supported by the Research Internships Abroad scholarship (2018/26306–2) from FAPESP to visit Margaret S. Robinson laboratory at the CIMR, University of Cambridge. L. A. T. was supported by postdoctoral fellowship (2021/01182–1) from FAPESP. L. L. P. d. S. is recipient of a long-standing investigator scholarship from CNPq. The authors declare no competing financial interest.

Conflict of interest—The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Abbreviations—The abbreviations used are: AP-1, the clathrin adaptor 1; BCS, bathocuproinedisulfonic acid; CCV, clathrin-coated vesicles; CI-MPR, Cation-Independent Mannose-6-phosphate receptor; ER, endoplasmic reticulum; IGF-II, insulin-like growth factor II; KD, knockdown; M6P, Mannose-6-phosphate; RUSH,

retention using selective hooks; SBP, streptavidin-binding peptide; TGN, trans-Golgi network.

References

1. Tong, P. Y., and Kornfeld, S. (1989) Ligand interactions of the cation-dependent mannose 6-phosphate receptor. Comparison with the cation-independent mannose 6-phosphate receptor. *J. Biol. Chem.* **264**, 7970–7975
2. Dahms, N. M., and Kornfeld, S. (1989) The cation-dependent mannose 6-phosphate receptor. Structural requirements for mannose 6-phosphate binding and oligomerization. *J. Biol. Chem.* [https://doi.org/10.1016/S0021-9258\(18\)60486-7](https://doi.org/10.1016/S0021-9258(18)60486-7)
3. Munier-Lehmann, H., Mauxion, F., Bauer, U., Lobel, P., and Hoflack, B. (1996) Re-expression of the mannose 6-phosphate receptors in receptor-deficient fibroblasts: complementary function of the two mannose 6-phosphate receptors in lysosomal enzyme targeting. *J. Biol. Chem.* **271**, 15166–15174
4. Staudt, C., Puissant, E., and Boonen, M. (2017) Subcellular trafficking of mammalian lysosomal proteins: an extended view. *Int. J. Mol. Sci.* **18**, 47
5. Coutinho, M. F., Prata, M. J., and Alves, S. (2012) Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. *Mol. Genet. Metab.* **105**, 542–550
6. Ghosh, P., Dahms, N. M., and Kornfeld, S. (2003) Mannose 6-phosphate receptors: new twists in the tale. *Nat. Rev. Mol. Cell Biol.* **4**, 202–213
7. Duncan, J. R., and Kornfeld, S. (1988) Intracellular movement of two mannose 6-phosphate receptors: return to the Golgi apparatus. *J. Cell Biol.* **106**, 617–628
8. Seaman, M. N. J., McCaffery, J. M., and Emr, S. D. (1998) A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. *J. Cell Biol.* **142**, 665–681
9. Seaman, M. N. J. (2004) Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer. *J. Cell Biol.* **165**, 111–122
10. Lin, S. X., Mallet, W. G., Huang, A. Y., and Maxfield, F. R. (2004) Endocytosed Cation-Independent Mannose 6-Phosphate Receptor Traffics via the Endocytic Recycling Compartment en Route to the trans-Golgi Network and a Subpopulation of Late Endosomes. *Mol. Biol. Cell* **15**, 721–733
11. Jin, M., Sahagian, G. G., and Snider, M. D. (1989) Transport of surface mannose 6-phosphate receptor to the Golgi complex in cultured human cells. *J. Biol. Chem.* [https://doi.org/10.1016/s0021-9258\(18\)83287-2](https://doi.org/10.1016/s0021-9258(18)83287-2)
12. Arighi, C. N., Harmell, L. M., Aguilar, R. C., Haft, C. R., and Bonifacino, J. S. (2004) Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. *J. Cell Biol.* **165**, 123–133
13. Ara, A., Ahmed, K. A., and Xiang, J. (2018) Mannose-6-phosphate receptor: a novel regulator of T cell immunity. *Cell. Mol. Immunol.* **15**, 986–988
14. Wang, Y., MacDonald, R. G., Thinakaran, G., and Kar, S. (2017) Insulin-like growth factor-II/cation-independent mannose 6-phosphate receptor in Neurodegenerative diseases. *Mol. Neurobiol.* **54**, 2636–2658
15. Wang, Y., Buggia-Prévo, V., Zavorcka, M. E., Bleackley, R. C., MacDonald, R. G., Thinakaran, G., et al. (2015) Overexpression of the insulin-like growth factor II receptor increases β -amyloid production and affects cell viability. *Mol. Cell. Biol.* **35**, 2368–2384
16. Polishchuk, R., and Lutsenko, S. (2013) Golgi in copper homeostasis: a view from the membrane trafficking field. *Histochem. Cell Biol.* **140**, 285–295
17. Yamaguchi, Y., Heiny, M. E., Suzuki, M., and Gitlin, J. D. (1996) Biochemical characterization and intracellular localization of the Menkes disease protein. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 14030–14035
18. Hung, I. H., Suzuki, M., Yamaguchi, Y., Yuan, D. S., Klausner, R. D., and Gitlin, J. D. (1997) Biochemical characterization of the Wilson disease protein and functional expression in the yeast *Saccharomyces cerevisiae*. *J. Biol. Chem.* **272**, 21461–21466
19. Petris, M. J., Mercer, J. F. B., Culvenor, J. G., Lockhart, P., Gleeson, P. A., and Camakaris, J. (1996) Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the

CI-MPR and ATP7B retrograde transport requires AP-1y2

- plasma membrane: a novel mechanism of regulated trafficking. *EMBO J.* **15**, 6084–6095
20. La Fontaine, S., Firth, S. D., Lockhart, P. J., Brooks, H., Parton, R. G., Camakaris, J., *et al.* (1998) Functional analysis and intracellular localization of the human Menkes protein (MNK) stably expressed from a cDNA construct in Chinese hamster ovary cells (CHO-K1). *Hum. Mol. Genet.* **7**, 1293–1300
 21. Roelofsen, H., Wolters, H., Van Luyn, M. J. A., Miura, N., Kuipers, F., and Vonk, R. J. (2000) Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. *Gastroenterology* **119**, 782–793
 22. Cater, M. A., La Fontaine, S., Shield, K., Deal, Y., and Mercer, J. F. B. (2006) ATP7B mediates vesicular sequestration of copper: insight into biliary copper excretion. *Gastroenterology* **130**, 493–506
 23. Duncan, M. C. (2022) New directions for the clathrin adaptor AP-1 in cell biology and human disease. *Curr. Opin. Cell Biol.* **76**, 102079
 24. Sanger, A., Hirst, J., Davies, A. K., and Robinson, M. S. (2019) Adaptor protein complexes and disease at a glance. *J. Cell Sci.* **132**, jcs222992
 25. Bonifacino, J. S. (2014) Adaptor proteins involved in polarized sorting. *J. Cell Biol.* **204**, 7–17
 26. Robinson, M. S. (2015) Forty years of clathrin-coated vesicles. *Traffic* **16**, 1210–1238
 27. Robinson, M. S., and Bonifacino, J. S. (2001) Adaptor-related proteins. *Curr. Opin. Cell Biol.* [https://doi.org/10.1016/S0955-0674\(00\)00235-0](https://doi.org/10.1016/S0955-0674(00)00235-0)
 28. Doray, B., Lee, I., Knisely, J., Bu, G., and Kornfeld, S. (2007) The $\gamma\sigma 1$ and $\alpha\sigma 2$ hemicomplexes of clathrin adaptors AP-1 and AP-2 Harbor the dileucine recognition site. *Mol. Biol. Cell.* **18**, 1887–1896
 29. Janvier, K., Kato, Y., Boehm, M., Rose, J. R., Martina, J. A., Kim, B. Y., *et al.* (2003) Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 $\gamma\sigma 1$ and AP-3 $\delta\sigma 3$ hemicomplexes. *J. Cell Biol.* **163**, 1281–1290
 30. Mattera, R., Boehm, M., Chaudhuri, R., Prabhu, Y., and Bonifacino, J. S. (2011) Conservation and diversification of dileucine signal recognition by adaptor protein (AP) complex variants. *J. Biol. Chem.* **286**, 2022–2030
 31. Ohno, H., Stewart, J., Fournier, M. C., Bosshart, H., Rhee, I., Miyatake, S., *et al.* (1995) Interaction of tyrosine-based sorting signals with clathrin-associated proteins. *Science* **269**, 1872–1875
 32. Ohno, H., Fournier, M. C., Poy, G., and Bonifacino, J. S. (1996) Structural determinants of interaction of tyrosine-based sorting signals with the adaptor medium chains. *J. Biol. Chem.* **271**, 29009–29015
 33. Owen, D. J., and Evans, P. R. (1998) A structural explanation for the recognition of tyrosine-based endocytotic signals. *Science* **282**, 1327–1332
 34. Waguri, S., Dewitte, F., Le Borgne, R., Rouillé, Y., Uchiyama, Y., Dubremetz, J. F., *et al.* (2003) Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells. *Mol. Biol. Cell.* **14**, 142–155
 35. Doray, B., Ghosh, P., Griffith, J., Geuze, H. J., and Kornfeld, S. (2002) Cooperation of GGAs and AP-1 in packaging MPRs at the trans-Golgi network. *Science* **297**, 1700–1703
 36. Klumperman, J., Hille, A., Veenendaal, T., Oorschot, V., Stoorvogel, W., Von Figura, K., *et al.* (1993) Differences in the endosomal distributions of the two mannose 6-phosphate receptors. *J. Cell Biol.* **121**, 997–1010
 37. Hirst, J., Borner, G. H. H., Antrobus, R., Peden, A. A., Hodson, N. A., Sahlender, D. A., *et al.* (2012) Distinct and overlapping roles for AP-1 and GGAs revealed by the “knocksideways” system. *Curr. Biol.* **22**, 1711–1716
 38. Huang, F., Nesterov, A., Carter, R. E., and Sorkin, A. (2001) Trafficking of yellow-fluorescent-protein-tagged $\mu 1$ subunit of clathrin adaptor AP-1 complex in living cells. *Traffic* **2**, 345–357
 39. Meyer, C., Zizioli, D., Lausmann, S., Eskelinen, E. L., Hamann, J., Saftig, P., *et al.* (2000) $\mu 1$ A-adaptin-deficient mice: lethality, loss of AP-1 binding and rerouting of mannose 6-phosphate receptors. *EMBO J.* **19**, 2193–2203
 40. Meyer, C., Eskelinen, E. L., Guruprasad, M. R., von Figura, K., and Schu, P. (2001) $\mu 1$ A deficiency induces a profound increase in MPR300/IGF-II receptor internalization rate. *J. Cell Sci.* **114**, 4469–4476
 41. Robinson, M. S., Sahlender, D. A., and Foster, S. D. (2010) Rapid inactivation of proteins by rapamycin-induced rerouting to mitochondria. *Dev. Cell.* **18**, 324–331
 42. Buser, D. P., Schleicher, K. D., Prescianotto-Baschong, C., and Spiess, M. (2018) A versatile nanobody-based toolkit to analyze retrograde transport from the cell surface. *Proc. Natl. Acad. Sci. U. S. A.* <https://doi.org/10.1073/pnas.1801865115>
 43. Braiterman, L., Nyasae, L., Leves, F., and Hubbard, A. L. (2011) Critical roles for the COOH terminus of the Cu-ATPase ATP7B in protein stability, trans-Golgi network retention, copper sensing, and retrograde trafficking. *Am. J. Physiol. Gastrointest. Liver Physiol.* **301**, G69–G81
 44. Lalioti, V., Hernandez-Tiedra, S., and Sandoval, I. V. (2014) DKWSLLL, a versatile DXXXLL-type signal with distinct roles in the Cu+-Regulated trafficking of ATP7B. *Traffic.* <https://doi.org/10.1111/tra.12176>
 45. Jain, S., Fariás, G. G., and Bonifacino, J. S. (2015) Polarized sorting of the copper transporter ATP7B in neurons mediated by recognition of a dileucine signal by AP-1. *Mol. Biol. Cell.* **26**, 218–228
 46. Hirst, J., Edgar, J. R., Borner, G. H. H., Li, S., Sahlender, D. A., Antrobus, R., *et al.* (2015) Contributions of epsinR and gadinin to clathrin-mediated intracellular trafficking. *Mol. Biol. Cell.* **26**, 3085–3103
 47. Yi, L., and Kaler, S. G. (2015) Direct interactions of adaptor protein complexes 1 and 2 with the copper transporter ATP7A mediate its anterograde and retrograde trafficking. *Hum. Mol. Genet.* **24**, 2411–2425
 48. Takatsu, H., Sakurai, M., Shin, H. W., Murakami, K., and Nakayama, K. (1998) Identification and characterization of novel clathrin adaptor-related proteins. *J. Biol. Chem.* **273**, 24693–24700
 49. Rost, M., Döring, T., and Prange, R. (2008) $\gamma 2$ -adaptin, a ubiquitin-interacting adaptor, is a substrate to coupled ubiquitination by the ubiquitin ligase nedd4 and functions in the endosomal pathway. *J. Biol. Chem.* **283**, 32119–32130
 50. Döring, T., Gotthardt, K., Stieler, J., and Prange, R. (2010) $\gamma 2$ -Adaptin is functioning in the late endosomal sorting pathway and interacts with ESCRT-I and -III subunits. *Biochim. Biophys. Acta Mol. Cell Res.* **1803**, 1252–1264
 51. Tavares, L. A., da Silva, E. M. L., da Silva-Januário, M. E., Januário, Y. C., de Cavalho, J. V., Czernisz, É. S., *et al.* (2017) CD4 downregulation by the HIV-1 protein Nef reveals distinct roles for the $\gamma 1$ and $\gamma 2$ subunits of the AP-1 complex in protein trafficking. *J. Cell Sci.* <https://doi.org/10.1242/jcs.192104>
 52. Tavares, L. A., de Carvalho, J. V., Costa, C. S., Silveira, R. M., de Carvalho, A. N., Donadi, E. A., *et al.* (2020) Two functional variants of AP-1 complexes composed of either $\gamma 2$ or $\gamma 1$ subunits are independently required for major histocompatibility complex class I downregulation by HIV-1 Nef. *J. Virol.* <https://doi.org/10.1128/JVI.02039-19>
 53. Aguilar, R. C., Boehm, M., Gorshkova, I., Crouch, R. J., Tomita, K., Saito, T., *et al.* (2001) Signal-binding specificity of the $\mu 4$ subunit of the adaptor protein complex AP-4. *J. Biol. Chem.* **276**, 13145–13152
 54. Fariás, G. G., Cuitino, L., Guo, X., Ren, X., Jarnik, M., Mattera, R., *et al.* (2012) Signal-mediated, AP-1/clathrin-dependent sorting of transmembrane receptors to the somatodendritic domain of hippocampal neurons. *Neuron* **75**, 810–823
 55. Negrodo, P. N., Edgar, J. R., Wrobel, A. G., Zaccari, N. R., Antrobus, R., Owen, D. J., *et al.* (2017) Contribution of the clathrin adaptor AP-1 subunit $\mu 1$ to acidic cluster protein sorting. *J. Cell Biol.* **216**, 2927–2943
 56. Patterson, G. H., Hirschberg, K., Polishchuk, R. S., Gerlich, D., Phair, R. D., and Lippincott-Schwartz, J. (2008) Transport through the Golgi apparatus by rapid partitioning within a two-phase membrane system. *Cell* **133**, 1055–1067
 57. Velasco, A., Hendricks, L., Moremen, K. W., Tulsiani, D. R. P., Touster, O., and Farquhar, M. G. (1993) Cell type-dependent variations in the subcellular distribution of α -mannosidase I and II. *J. Cell Biol.* **122**, 39–51
 58. Li, Z., Michael, I. P., Zhou, D., Nagy, A., and Rini, J. M. (2013) Simple piggyBac transposon-based mammalian cell expression system for inducible protein production. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 5004–5009
 59. Seaman, M. N. J. (2007) Identification of a novel conserved sorting motif required for retromer-mediated endosome-to-TGN retrieval. *J. Cell Sci.* **120**, 2378–2389

60. Boncompain, G., Divoux, S., Gareil, N., De Forges, H., Lescure, A., Latreche, L., *et al.* (2012) Synchronization of secretory protein traffic in populations of cells. *Nat. Methods* **9**, 493–498
61. Munro, S., and Pelham, H. R. B. (1987) A C-terminal signal prevents secretion of luminal ER proteins. *Cell*. [https://doi.org/10.1016/0092-8674\(87\)90086-9](https://doi.org/10.1016/0092-8674(87)90086-9)
62. Carosi, J. M., Denton, D., Kumar, S., and Sargeant, T. J. (2023) Receptor recycling by retromer. *Mol. Cell. Biol.* **43**, 317–334
63. Johannes, L., and Wunder, C. (2011) Retrograde transport: two (or more) roads diverged in an endosomal tree? *Traffic* **12**, 956–962
64. Hinners, I., and Tooze, S. A. (2003) Changing directions: clathrin-mediated transport between the Golgi and endosomes. *J. Cell Sci.* **116**, 763–771
65. Tu, Y., Zhao, L., Billadeau, D. D., and Jia, D. (2020) Endosome-to-TGN trafficking: organelle-vesicle and organelle-organelle interactions. *Front. Cell Dev. Biol.* <https://doi.org/10.3389/fcell.2020.00163>
66. Hirst, J., Sahlender, D. A., Choma, M., Sinka, R., Harbour, M. E., Parkinson, M., *et al.* (2009) Spatial and functional relationship of GGAs and AP-1 in *Drosophila* and HeLa cells. *Traffic* **10**, 1696–1710
67. Puertollano, R., Van der Wel, N. N., Greene, L. E., Eisenberg, E., Peters, P. J., and Bonifacino, J. S. (2003) Morphology and dynamics of clathrin/GGA1-coated carriers budding from the trans-Golgi network. *Mol. Biol. Cell.* **14**, 1545–1557
68. Gravotta, D., Bay, A. P., Jonker, C. T. H., Zager, P. J., Benedicto, I., Schreiner, R., *et al.* (2019) Clathrin and clathrin adaptor AP-1 control apical trafficking of megalin in the biosynthetic and recycling routes. *Mol. Biol. Cell* **30**, 1716–1728
69. Zizioli, D., Geumann, C., Kratzke, M., Mishra, R., Borsani, G., Finazzi, D., *et al.* (2017) $\gamma 2$ and $\gamma 1$ AP-1 complexes: different essential functions and regulatory mechanisms in clathrin-dependent protein sorting. *Eur. J. Cell Biol.* **96**, 356–368
70. Saint-Pol, A., Yélamos, B., Amessou, M., Mills, I. G., Dugast, M., Tenza, D., *et al.* (2004) Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. *Dev. Cell*. [https://doi.org/10.1016/S1534-5807\(04\)00100-5](https://doi.org/10.1016/S1534-5807(04)00100-5)
71. Hirst, J., Miller, S. E., Taylor, M. J., Von Mollard, G. F., and Robinson, M. S. (2004) EpsinR is an adaptor for the SNARE protein Vti1b. *Mol. Biol. Cell.* **15**, 5593–5602
72. Wahle, T., Prager, K., Raffler, N., Haass, C., Famulok, M., and Walter, J. (2005) GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. *Mol. Cell. Neurosci.* **29**, 453–461
73. Holloway, Z. G., Velayos-Baeza, A., Howell, G. J., Levecque, C., Pon-nambalam, S., Sztul, E., *et al.* (2013) Trafficking of the Menkes copper transporter ATP7A is regulated by clathrin-, AP-2-, AP-1-, and Rab22-dependent steps. *Mol. Biol. Cell.* **24**, 1735–1748
74. Buser, D. P., and Spang, A. (2023) Protein sorting from endosomes to the TGN. *Front. Cell Dev. Biol.* <https://doi.org/10.3389/fcell.2023.1140605>
75. Seaman, M. N. J. (2012) The retromer complex-endosomal protein recycling and beyond. *J. Cell Sci.* <https://doi.org/10.1242/jcs.103440>
76. Burd, C., and Cullen, P. J. (2014) Retromer: a master conductor of endosome sorting. *Cold Spring Harb. Perspect. Biol.* **6**, a016774
77. Gallon, M., and Cullen, P. J. (2015) Retromer and sorting nexins in endosomal sorting. *Biochem. Soc. Trans.* **43**, 33–47
78. Popoff, V., Mardones, G. A., Tenza, D., Rojas, R., Lamaze, C., Bonifacino, J. S., *et al.* (2007) The retromer complex and clathrin define an early endosomal retrograde exit site. *J. Cell Sci.* **120**, 2022–2031
79. Progida, C., Cogli, L., Piro, F., De Luca, A., Bakke, O., and Bucci, C. (2010) Rab7b controls trafficking from endosomes to the TGN. *J. Cell Sci.* **123**, 1480–1491
80. Kucera, A., Borg Distefano, M., Berg-Larsen, A., Skjeldal, F., Repnik, U., Bakke, O., *et al.* (2016) Spatiotemporal resolution of Rab9 and CI-MPR dynamics in the endocytic pathway. *Traffic* **17**, 211–229
81. Borner, G. H. H., Harbour, M., Hester, S., Lilley, K. S., and Robinson, M. S. (2006) Comparative proteomics of clathrin-coated vesicles. *J. Cell Biol.* **175**, 571–578
82. Popoff, V., Mardones, G. A., Bai, S. K., Chambon, V., Tenza, D., Burgos, P. V., *et al.* (2009) Analysis of articulation between clathrin and retromer in retrograde sorting on early endosomes. *Traffic* **10**, 1868–1880
83. Shi, A., Sun, L., Banerjee, R., Tobin, M., Zhang, Y., and Grant, B. D. (2009) Regulation of endosomal clathrin and retromer-mediated endosome to Golgi retrograde transport by the J-domain protein RME-8. *EMBO J.* **28**, 3290–3302
84. McGough, I. J., and Cullen, P. J. (2013) Clathrin is not required for SNX-BAR-retromer-mediated carrier formation. *J. Cell Sci.* **126**, 45–52
85. McGough, I. J., and Cullen, P. J. (2011) Recent advances in retromer biology. *Traffic* **12**, 963–971
86. Simonetti, B., Danson, C. M., Heesom, K. J., and Cullen, P. J. (2017) Sequence dependent cargo recognition by SNX-BARs mediates retromer independent transport of CI-MPR. *J. Cell Biol.* **216**, 3695–3712
87. Kvainickas, A., Jimenez-Organ, A., Nägele, H., Hu, Z., Dengjel, J., and Steinberg, F. (2017) Cargo-selective SNX-BAR proteins mediate retromer trimer independent retrograde transport. *J. Cell Biol.* **216**, 3677–3693
88. Simonetti, B., Paul, B., Chaudhari, K., Weeratunga, S., Steinberg, F., Gorla, M., *et al.* (2019) Molecular identification of a BAR domain-containing coat complex for endosomal recycling of transmembrane proteins. *Nat. Cell Biol.* **21**, 1219–1233
89. Lubben, N. B., Sahlender, D. A., Motley, A. M., Lehner, P. J., Benaroch, P., and Robinson, M. S. (2007) HIV-1 Nef-induced down-regulation of MHC class I requires AP-1 and clathrin but not PACS-1 and is impeded by AP-2. *Mol. Biol. Cell* **18**, 3351–3365
90. daSilva, L. L., Sougrat, R., Burgos, P. V., Janvier, K., Mattera, R., and Bonifacino, J. S. (2009) Human immunodeficiency virus type 1 Nef protein targets CD4 to the multivesicular body pathway. *J. Virol.* **83**, 6578–6590
91. Guo, X., Mattera, R., Ren, X., Chen, Y., Retamal, C., González, A., *et al.* (2013) The adaptor protein-1 μ 1B subunit expands the repertoire of basolateral sorting signal recognition in epithelial cells. *Dev. Cell.* **27**, 353–366
92. Haft, C. R., De La, M., Sierra, L., Bafford, R., Lesniak, M. A., Barr, V. A., *et al.* (2000) Human orthologs of yeast vacuolar protein sorting proteins Vps26, 29, and 35: assembly into multimeric complexes. *Mol. Biol. Cell* **11**, 4105–4116
93. Januário, Y. C., Eden, J., de Oliveira, L. S., De Pace, R., Tavares, L. A., da Silva-Januário, M. E., *et al.* (2022) Clathrin adaptor AP-1-mediated Golgi export of amyloid precursor protein is crucial for the production of neurotoxic amyloid fragments. *J. Biol. Chem.* **298**, 102172
94. Hirst, J., Itzhak, D. N., Antrobus, R., Borner, G. H. H., and Robinson, M. S. (2018) Role of the AP-5 adaptor protein complex in late endosome-to-Golgi retrieval. *PLoS Biol.* **16**, e2004411
95. De Carvalho, J. V., De Castro, R. O., Da Silva, E. Z. M., Silveira, P. P., Da Silva-Januário, M. E., Arruda, E., *et al.* (2014) Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. *PLoS One* **9**, e113691
96. Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., *et al.* (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* **31**, 827–832
97. Rojas, R., Kametaka, S., Haft, C. R., and Bonifacino, J. S. (2007) Interchangeable but essential functions of SNX1 and SNX2 in the association of retromer with endosomes and the trafficking of mannose 6-phosphate receptors. *Mol. Cell. Biol.* **27**, 1112–1124
98. Cardoso, R. S., Tavares, L. A., Jesus, B. L. S., Criado, M. F., de Carvalho, A. N., Souza, J. de P., *et al.* (2020) Host retromer protein sorting nexin 2 interacts with human respiratory syncytial virus structural proteins and is required for efficient viral production. *MBio*. <https://doi.org/10.1128/mBio.01869-20>
99. DaSilva, L. L. P., Wall, M. J., de Almeida, L. P., Wauters, S. C., Januário, Y. C., Müller, J., *et al.* (2016) Activity-regulated cytoskeleton-associated protein controls AMPAR endocytosis through a direct interaction with clathrin-adaptor protein 2. *eNeuro* **3**. <https://doi.org/10.1523/ENEURO.0144-15.2016>
100. Abramoff, M. D., Magalhães, P. J., and Ram, S. J. (2004) Image processing with imageJ. *Biophotonics Int.* **11**, 36–42